Research Topics
| Peter MerkelSummaryAffiliation: Boston University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue diseasesP A Merkel
Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
J Rheumatol 26:591-6. 1999..We evaluated the diagnostic utility of a new aPL antibody test kit with a unique phospholipid mixture designed to be more specific than the standard anticardiolipin ELISA...- Part 1: The need for novel treatment regimens for ANCA-associated vasculitisP A Merkel
Boston University School of Medicine, Boston, MA 02118, USA
Clin Exp Rheumatol 25:S72-3. 2007 
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trialPeter A Merkel
Boston University School of Medicine, Boston, MA 02118, USA
Arthritis Rheum 59:699-705. 2008..To determine the validity, reliability, and feasibility of durometer measurements of skin hardness as an outcome measure in clinical trials of scleroderma...- The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitisPeter A Merkel
Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, USA
J Rheumatol 38:1480-6. 2011..This report reviews the domains of illness in AAV included in the OMERACT core set, describes the instruments validated to measure these domains, and presents the approved core set... 
Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitisP A Merkel
Vasculitis Center, E5, Boston University School of Medicine, 72 East Concord Street, Boston, Massachussets, 02118, USA
Ann Rheum Dis 68:103-6. 2009..An exercise comparing six different vasculitis instruments was performed...- Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9Peter A Merkel
Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA 02118, USA
J Rheumatol 36:2362-8. 2009..This process has been informed by several ongoing projects providing data on outcomes of disease activity, disease-related damage, multidimensional health-related quality of life, and patient-reported ratings of the burden of vasculitis... - Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7Peter A Merkel
Boston University School of Medicine, Boston, MA 02118, USA
J Rheumatol 32:2488-95. 2005.... - Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6Peter A Merkel
Arthritis Center, Section of Rheumatology, Boston University School of Medicine, Boston, MA 02118, USA
J Rheumatol 30:1630-47. 2003..The current level of validation of outcome measures in SSc is assessed according to the guidelines set forth by prior OMERACT meetings... - Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) StudyPeter A Merkel
Boston University School of Medicine, Vasculitis Center, E 5, 715 Albany Street, Boston, MA 02118, USA
Ann Intern Med 142:620-6. 2005..Venous thrombotic events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known... - Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonPeter A Merkel
Harvard Medical School, Boston, Massachusetts, USA
Arthritis Rheum 46:2410-20. 2002.... - Evaluation and treatment of vasculitis in the critically ill patientPeter A Merkel
Rheumatology Section, Boston Medical Center, Arthritis Center, Boston University School of Medicine, 730 Albany Street, Boston, MA 02118, USA
Crit Care Clin 18:321-44. 2002..Rapid initiation of immunosuppressive therapy for critically ill patients with vasculitis is crucial and may be life-saving... - Drug-induced vasculitisP A Merkel
Arthritis Center, Boston University School of Medicine, and Rheumatology Section, Boston University Medical Center, Boston, Massachusetts, USA
Rheum Dis Clin North Am 27:849-62. 2001..Increasing understanding of the pathophysiologic characteristics of all inflammatory vasculitides should lead to better diagnostic and therapeutic approaches to DIV... - Rituximab versus cyclophosphamide for ANCA-associated vasculitisJohn H Stone
Massachusetts General Hospital, Boston, USA
N Engl J Med 363:221-32. 2010..Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based regimen... - B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosisRobert Lafyatis
Boston University School of Medicine, Boston, Massachusetts 02118, USA
Arthritis Rheum 60:578-83. 2009.... - Genetics of vasculitisPaul A Monach
Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts 02118, USA
Curr Opin Rheumatol 22:157-63. 2010..Cohorts have been assembled that are of sufficient size to allow application of up-to-date methods of genetic analysis. This review will summarize the current understanding of the genetics of several forms of vasculitis... - Durometry for the assessment of skin disease in systemic sclerosisEugene Y Kissin
Boston University School of Medicine, Boston, Massachusetts 02118, USA
Arthritis Rheum 55:603-9. 2006..Durometry should be considered for use in clinical therapeutic SSc trials... - Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trialDinesh Khanna
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, Los Angeles, California, USA
J Rheumatol 32:832-40. 2005.... - Thromboembolic disease in vasculitisGunnar Tomasson
The Vasculitis Center, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts 02118, USA
Curr Opin Rheumatol 21:41-6. 2009..To give an overview of recent clinical findings of thromboembolic disease in vasculitis and provide insight into possible explanations of the association between thrombosis and inflammation... - Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, California 90095, USA
Ann Rheum Dis 67:703-9. 2008..To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc)... - The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic eventJodi K Sebastian
Boston University School of Medicine, Boston, Massachusetts 02118, USA
J Rheumatol 34:2446-50. 2007..The frequency of anticardiolipin antibodies (aCL), anti-beta2-glycoprotein antibodies (anti-beta2-GP), and several genetic hypercoagulable factors were examined in a large cohort of patients with WG... - Case records of the Massachusetts General Hospital. Case 31-2008. A 39-year-old man with chest pain, arthralgias, and a mediastinal massPeter A Merkel
Arthritis Center, Boston Medical Center, and the Department of Medicine, Boston University School of Medicine, Boston, USA
N Engl J Med 359:1603-14. 2008 - Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestationsJodi K Sebastian
Boston University, Boston, Massachusetts 02118, USA
J Rheumatol 34:1027-31. 2007..We examined a large, well-characterized cohort of patients with WG and active disease for the presence of AECA... - Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosisEugene Y Kissin
Boston University Medical Center, Boston, Massachusetts, USA
Arthritis Rheum 54:3655-60. 2006..To investigate the correlation between the degree of dermal fibrosis and myofibroblast infiltration using clinical assessments of skin thickness and hardness in systemic sclerosis (SSc)... - Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agendaHaner Direskeneli
Marmara University School of Medicine, Istanbul, Turkey
J Rheumatol 38:1471-9. 2011.... - Nutrient status of adults with cystic fibrosisCatherine M Gordon
Division of Endocrinology, Children s Hospital Boston, Boston, MA 22015, USA
J Am Diet Assoc 107:2114-9. 2007..These findings call into question the applicability of established nutrient thresholds for patients with cystic fibrosis... - Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysisAlfred D Mahr
Vasculitis Center, Boston University School of Medicine, 75 Albany Street, Boston, MA 02118, USA
Arthritis Rheum 56:2789-97. 2007..To reevaluate the efficacy and safety of adjunctive low-dose methotrexate (MTX) in giant cell arteritis (GCA)... - Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosisAlfred D Mahr
Boston University, Boston, Massachusetts 02118, USA
Arthritis Rheum 59:884-91. 2008..To assess the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) with respect to its selection and weighting of items... - A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritisGary S Hoffman
Cleveland Clinic Foundation, Cleveland, Ohio 44915, USA
Arthritis Rheum 46:1309-18. 2002.... - A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diArnold E Postlethwaite
University of Tennessee, Memphis, and VAMC, Memphis
Arthritis Rheum 58:1810-22. 2008..To investigate the safety and efficacy of oral bovine type I collagen (CI) treatment in patients who have had diffuse cutaneous systemic sclerosis (dcSSc; scleroderma) for <or=10 years... - Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosisJavier D Finkielman
Mayo Clinic, Rochester, Minnesota 55905, USA
Ann Intern Med 147:611-9. 2007..The utility of antineutrophil cytoplasmic antibody (ANCA) levels to guide the management of patients with Wegener granulomatosis remains controversial... - Outcome measurements in scleroderma: results from a delphi exerciseHashim Gazi
Division of Rheumatology, Department of Medicine, The University of Western Ontario, London, Ontario, Canada
J Rheumatol 34:501-9. 2007..To obtain a consensus on the minimal clinically relevant treatment effect in various scleroderma disease outcome measures to be used in future clinical trials... - Scleroderma--developing measures of responseDaniel E Furst
University of California at Los Angeles, CA 90025, USA
J Rheumatol 32:2477-80. 2005..Deliberations focused on progress in the assessment of gastrointestinal disease, renal physiology, vascular damage, and the unique challenges inherent in studying pediatric patients with scleroderma... - Outcome measures in systemic sclerosis: an update on instruments and current researchDinesh Khanna
Division of Immunology, Department of Internal Medicine, University of Cincinnati, PO Box 670563, Cincinnati, OH 45267 0563, USA
Curr Rheumatol Rep 9:151-7. 2007..This review provides an update on currently used outcome measures in SSc with specific attention on newer tools and also describes methodology under development... - EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitisBernhard Hellmich
Department of Rheumatology, University Hospital of Schleswig Holstein, Campus Lubeck, Lubeck, Germany
Ann Rheum Dis 66:605-17. 2007..To develop the European League Against Rheumatism (EULAR) recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis... - Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trialGary S Hoffman
Center for Vasculitis Care and Research, The Cleveland Clinic Foundation, Lerner College of Medicine, Cleveland, Ohio 44195, USA
Ann Intern Med 146:621-30. 2007..Tumor necrosis factor-alpha is present in arteries in giant cell arteritis... - Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192Christopher P Denton
Royal Free Hospital, London, UK
Arthritis Rheum 56:323-33. 2007..To evaluate CAT-192, a recombinant human antibody that neutralizes transforming growth factor beta1 (TGFbeta1), in the treatment of early-stage diffuse cutaneous systemic sclerosis (dcSSc)... - Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)Philip Seo
Johns Hopkins University, Baltimore, Maryland
Arthritis Rheum 52:2168-78. 2005..An important measure of future therapeutic approaches will be their ability to reduce the damage accrued over time... - Hearing loss in Wegener's granulomatosisSivasanker Bakthavachalam
Department of Otolaryngology-Head and Neck Surgery, Boston University School of Medicine, Boston, Massachusetts 02118, USA
Otol Neurotol 25:833-7. 2004..These data suggest that it may be appropriate to obtain screening audiograms in all patients with newly diagnosed or relapsing Wegener's granulomatosis... - Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritisGary S Hoffman
Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Arthritis Rheum 50:2296-304. 2004..In this study, we assessed therapy with anti-TNF agents in patients with TA that was not controlled by glucocorticoid therapy or other immunosuppressants... - Solid malignancies among patients in the Wegener's Granulomatosis Etanercept TrialJohn H Stone
Johns Hopkins University, Baltimore, Maryland, USA
Arthritis Rheum 54:1608-18. 2006..This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients... - ANCA are detectable in nearly all patients with active severe Wegener's granulomatosisJavier D Finkielman
Thoracic Disease Research Unit, Division of Pulmonary and Critical Care Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
Am J Med 120:643.e9-14. 2007..The objective of this study was to determine the frequency of ANCA in patients with active Wegener's granulomatosis and to assess the influence of disease severity on test results... - A serum proteomic approach to gauging the state of remission in Wegener's granulomatosisJohn H Stone
The Johns Hopkins Vasculitis Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
Arthritis Rheum 52:902-10. 2005..To identify serum ion patterns that distinguish remission from active disease in patients with Wegener's granulomatosis (WG)... - Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunctionDimitrios Vassilopoulos
The Henry Dunant Hospital, Athens, Greece
Arthritis Rheum 49:151-5. 2003.... - Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysisOliver Distler
University Hospital Zurich, Zurich, Switzerland
Arthritis Rheum 59:867-75. 2008..The aim of the present study was to establish an expert consensus regarding which outcome measures are most appropriate for clinical trials in PAH-SSc... - Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part ICharles G Helmick
CDC, Atlanta, Georgia 30341 3717, USA
Arthritis Rheum 58:15-25. 2008..A companion article (part II) addresses additional conditions... - The future of damage assessment in vasculitisPhilip Seo
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Rheumatol 34:1357-71. 2007..This initiative is part of a larger international effort to create a unified approach to disease assessment for the primary systemic vasculitides... - Herpes zoster in immunocompromised patients: incidence, timing, and risk factorsPeter K Wung
Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, MD, USA
Am J Med 118:1416. 2005..These data may inform studies of interventions designed to prevent herpes zoster in patients on treatment for immune-mediated diseases...
Research Grants
- Plasma Exchange and Glucocorticoids for Treatment of ANCA-Associated VasculitisPeter Merkel; Fiscal Year: 2009..This application seeks funding to support 5 study sties in the United States and combine resources with funding from the United Kingdom. ..
- Vasculitis Outcome Measures: Development and ValidationPeter Merkel; Fiscal Year: 2006..I.s, Drs. John Stone and Peter Merkel. There are two Specific Aims: Aim 1: To develop and validate a consensus disease activity measure for ANCA-..
- Clinical Research for Rare Diseases: Opportunities, Challenges, and SolutionsPeter Merkel; Fiscal Year: 2007..Finally, the proceedings will be posted on the web and a summary article will be published. If this conference proves successful, we plan on having similar sessions attached to future RDCRC meetings. ..
- Vasculitis Clinical Research Network (VCRN)Peter Merkel; Fiscal Year: 2006..AIM 5. Build and contribute to an electronic website resource with substantive content for clinicians, researchers, and patients. ..
- Studies in Scleroderma and Cystic Fibrosis OsteoporosisPeter Merkel; Fiscal Year: 2005..A unique seminar and a series of support services at the host institution will further complement the training program. ..
- Plasma Exchange and Glucocorticoids for Treatment of ANCA-Associated VasculitisPeter A Merkel; Fiscal Year: 2010..This application seeks funding to support 5 study sties in the United States and combine resources with funding from the United Kingdom. ..